The Sterility Testing Market is gaining momentum as manufacturers strengthen quality systems for sterile medicines, biologics, and advanced therapies. From USD 1.69 billion in 2025, the market is expected to grow to USD 5.15 billion by 2035 at an 11.85% CAGR. Regulatory pressure and the expansion of biopharmaceutical manufacturing are among the major factors influencing market development.

Kits and reagents held the largest product-type position in 2025, representing approximately 46.4% of market revenue. Their recurring use in laboratory workflows creates consistent demand, while instruments support laboratories transitioning toward automated and rapid microbial detection technologies.

Services are also becoming increasingly important as pharmaceutical companies outsource specialized quality-control activities to contract testing organizations. The services segment is forecast to expand at an 11.38% CAGR through 2035, reflecting the growing role of external laboratories and contract development and manufacturing organizations in sterile production.

North America continues to lead the global market, while Europe benefits from stringent contamination-control requirements and established pharmaceutical manufacturing capabilities. Asia-Pacific offers particularly strong opportunities because of expanding biologics production, vaccine manufacturing, biosimilar development, and investment in GMP-certified facilities.

The future outlook is increasingly centered on rapid and automated testing. Traditional sterility testing can require extended incubation periods, encouraging manufacturers to evaluate validated rapid methods based on technologies such as ATP bioluminescence, molecular detection, and flow cytometry. As regulatory acceptance expands, faster testing could become an important competitive advantage for pharmaceutical quality-control operations.